Mineralocorticoids restore quiescent morphology and reduce VEGF receptor expression in inflamed choroidal endothelial cells in vitro

Melinda Fitzgerald; Lauren Evill; Kelly Banz; S. Carroll; Jennifer Rodger

doi:10.1159/000164799

Mineralocorticoids restore quiescent morphology and reduce VEGF receptor expression in inflamed choroidal endothelial cells in vitro

Melinda Fitzgerald, Lauren Evill, Kelly Banz, S. Carroll, Jennifer Rodger

Research output: Contribution to journal › Article › peer-review

Abstract

Background/Aims: While the glucocorticoid triamcinolone acetonide (9α-fluoro-16α-hydroxyprednisolone, TA) has been widely administered as a treatment of ocular inflammation, mineralocorticoids have not been tested for their efficacy. Methods: We assessed cellular morphology and actin distribution by immunomicroscopy and light microscopy, membrane permeability with transendothelial resistance and cell surface vascular endothelial growth factor receptor-1 (VEGF-R1) expression by flow cytometry. Results: Fludrocortisone acetate was more effective than TA in restoring quiescent morphology and reducing membrane permeability in phorbol-12-myristate-acetate (PMA)-stimulated choroidal endothelial cells (CECs). Each of the corticosteroids inhibited VEGF-R1 cell surface expression in PMA-responsive CECs. Conclusion: Mineralocorticoids may be of potential use in reducing vascular permeability in ocular disease.

Original language	English
Pages (from-to)	44-52
Journal	Ophthalmic research
Volume	41
Issue number	1
DOIs	https://doi.org/10.1159/000164799
Publication status	Published - 2009

Access to Document

10.1159/000164799

Cite this

@article{45310cf2d8074fa793a1cc9269559074,

title = "Mineralocorticoids restore quiescent morphology and reduce VEGF receptor expression in inflamed choroidal endothelial cells in vitro",

abstract = "Background/Aims: While the glucocorticoid triamcinolone acetonide (9α-fluoro-16α-hydroxyprednisolone, TA) has been widely administered as a treatment of ocular inflammation, mineralocorticoids have not been tested for their efficacy. Methods: We assessed cellular morphology and actin distribution by immunomicroscopy and light microscopy, membrane permeability with transendothelial resistance and cell surface vascular endothelial growth factor receptor-1 (VEGF-R1) expression by flow cytometry. Results: Fludrocortisone acetate was more effective than TA in restoring quiescent morphology and reducing membrane permeability in phorbol-12-myristate-acetate (PMA)-stimulated choroidal endothelial cells (CECs). Each of the corticosteroids inhibited VEGF-R1 cell surface expression in PMA-responsive CECs. Conclusion: Mineralocorticoids may be of potential use in reducing vascular permeability in ocular disease.",

author = "Melinda Fitzgerald and Lauren Evill and Kelly Banz and S. Carroll and Jennifer Rodger",

year = "2009",

doi = "10.1159/000164799",

language = "English",

volume = "41",

pages = "44--52",

journal = "Ophthalmic research",

issn = "0030-3747",

publisher = "S Karger AG",

number = "1",

}

TY - JOUR

T1 - Mineralocorticoids restore quiescent morphology and reduce VEGF receptor expression in inflamed choroidal endothelial cells in vitro

AU - Fitzgerald, Melinda

AU - Evill, Lauren

AU - Banz, Kelly

AU - Carroll, S.

AU - Rodger, Jennifer

PY - 2009

Y1 - 2009

N2 - Background/Aims: While the glucocorticoid triamcinolone acetonide (9α-fluoro-16α-hydroxyprednisolone, TA) has been widely administered as a treatment of ocular inflammation, mineralocorticoids have not been tested for their efficacy. Methods: We assessed cellular morphology and actin distribution by immunomicroscopy and light microscopy, membrane permeability with transendothelial resistance and cell surface vascular endothelial growth factor receptor-1 (VEGF-R1) expression by flow cytometry. Results: Fludrocortisone acetate was more effective than TA in restoring quiescent morphology and reducing membrane permeability in phorbol-12-myristate-acetate (PMA)-stimulated choroidal endothelial cells (CECs). Each of the corticosteroids inhibited VEGF-R1 cell surface expression in PMA-responsive CECs. Conclusion: Mineralocorticoids may be of potential use in reducing vascular permeability in ocular disease.

AB - Background/Aims: While the glucocorticoid triamcinolone acetonide (9α-fluoro-16α-hydroxyprednisolone, TA) has been widely administered as a treatment of ocular inflammation, mineralocorticoids have not been tested for their efficacy. Methods: We assessed cellular morphology and actin distribution by immunomicroscopy and light microscopy, membrane permeability with transendothelial resistance and cell surface vascular endothelial growth factor receptor-1 (VEGF-R1) expression by flow cytometry. Results: Fludrocortisone acetate was more effective than TA in restoring quiescent morphology and reducing membrane permeability in phorbol-12-myristate-acetate (PMA)-stimulated choroidal endothelial cells (CECs). Each of the corticosteroids inhibited VEGF-R1 cell surface expression in PMA-responsive CECs. Conclusion: Mineralocorticoids may be of potential use in reducing vascular permeability in ocular disease.

U2 - 10.1159/000164799

DO - 10.1159/000164799

M3 - Article

C2 - 18946227

SN - 0030-3747

VL - 41

SP - 44

EP - 52

JO - Ophthalmic research

JF - Ophthalmic research

IS - 1

ER -

Mineralocorticoids restore quiescent morphology and reduce VEGF receptor expression in inflamed choroidal endothelial cells in vitro

Abstract

Access to Document

Fingerprint

Cite this